Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ocular Therapeutix (OCUL) Cost of Revenue (2016 - 2026)

Ocular Therapeutix has reported Cost of Revenue over the past 14 years, most recently at $1.3 million for Q1 2026.

  • For Q1 2026, Cost of Revenue fell 90.61% year-over-year to $1.3 million; the TTM value through Mar 2026 reached $18.0 million, down 34.44%, while the annual FY2025 figure was $53.9 million, 858.44% up from the prior year.
  • Cost of Revenue for Q1 2026 was $1.3 million at Ocular Therapeutix, down from $13.0 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $36.7 million in Q4 2023 and troughed at $1.0 million in Q4 2022.
  • A 5-year average of $7.4 million and a median of $1.9 million in 2025 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 3521.94% in 2023 and later plummeted 96.64% in 2024.
  • Year by year, Cost of Revenue stood at $1.0 million in 2022, then skyrocketed by 3521.94% to $36.7 million in 2023, then plummeted by 96.64% to $1.2 million in 2024, then soared by 953.41% to $13.0 million in 2025, then crashed by 89.74% to $1.3 million in 2026.
  • Business Quant data shows Cost of Revenue for OCUL at $1.3 million in Q1 2026, $13.0 million in Q4 2025, and $1.8 million in Q3 2025.